EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308137 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Amir H Meghdadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Brain Monitoring, Inc., Carlsbad, CA, United States of America. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Alzheimer Disease, Electroencephalography, Evoked Potentials. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
Cognitive decline in Alzheimer’s disease is associated with electroencephalographic (EEG) biosignatures even at early stages of mild cognitive impairment (MCI). The aim of this work is to provide a unified measure of cognitive decline by aggregating biosignatures from multiple EEG modalities and to evaluate repeatability of the composite measure at an individual level. These modalities included resting state EEG (eyes-closed) and two event-related potential (ERP) tasks on visual memory and attention. We compared individuals with MCI (n = 38) to age-matched healthy controls HC (n = 44). In resting state EEG, the MCI group exhibited higher power in Theta (3-7Hz) and lower power in Beta (13-20Hz) frequency bands. In both ERP tasks, the MCI group exhibited reduced ERP late positive potential (LPP), delayed ERP early component latency, slower reaction time, and decreased response accuracy. Cluster-based permutation analysis revealed significant clusters of difference between the MCI and HC groups in the frequency-channel and time-channel spaces. Cluster-based measures and performance measures (12 biosignatures in total) were selected as predictors of MCI. We trained a support vector machine (SVM) classifier achieving AUC = 0.89, accuracy = 77% in cross-validation using all data. Split-data validation resulted in (AUC = 0.87, accuracy = 76%) and (AUC = 0.75, accuracy = 70%) on testing data at baseline and follow-up visits, respectively. Classification scores at baseline and follow-up visits were correlated (r = 0.72, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Advanced Brain Monitoring, Inc., Carlsbad, CA, United States of America.
- Massachusetts General Hospital, Boston, MA, United States of America.
- Harvard Medical School, Boston, MA, United States of America.
- Scripps Health, La Jolla, CA, United States of America.
- Departments of Neurology and Medicine, Division of Pulmonary and Critical Care Medicine, Center for Sleep Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, United States of America.
- Department of Clinical and Translational Research, Mayo Clinic Health System Southwest Wisconsin, La Crosse, WI, United States of America.
ORCID-Profile: Amir H Meghdadi
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Meghdadi, A. H., Salat, D., Hamilton, J., Hong, Y., Boeve, B. F., St Louis, E. K., Verma, A., & Berka, C. (2024). EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0308137
Vancouver
Meghdadi AH, Salat D, Hamilton J, Hong Y, Boeve BF, St Louis EK, et al. EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease. PLOS ONE. 2024. doi:10.1371/journal.pone.0308137
BibTeX
@article{Meghdadi2024,
author = {Meghdadi, Amir H and Salat, David and Hamilton, Joanne and Hong, Yue and Boeve, Bradley F and St Louis, Erik K and Verma, Ajay and Berka, Chris},
title = {EEG and ERP biosignatures of mild cognitive impairment for longitudinal monitoring of early cognitive decline in Alzheimer’s disease},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308137}
}
EUVIMED